MELVILLE, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today provided an update on its business. "We have successfully executed against key strategic priorities since the start of the year," said Lance Alstodt, BioRestorative's Chief Executive Officer. "The most important of those were to advance our lead clinical program, BRTX-100, and expand our core preclinica ...